PTGX

Protagonist Therapeutics, Inc.
CAPPED RATING

Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Protagonist Therapeutics, Inc. (PTGX) is rated C (2.4/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B); its weakest is Growth (F).

Quantitative Factor Evaluation • Updated

Overall Rating
2.4 / 5.0
C
Value
C+
Factor Score 2.7 / 5.0
Growth
F
Factor Score 0.3 / 5.0
Profitability
B-
Factor Score 3.0 / 5.0
Momentum
B
Factor Score 3.3 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 28.4
EV / EBITDA 23.9
Rev Growth YoY N/M
Gross Margin N/M
Price Return 3M -17.4%
Price Return 12M 54.3%
Catalyst Signal 0.00
Market Cap $8.5B
TTM Revenue $551.7M
Price / Sales 15.5
ROE 39.6%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-14 C+ (2.7) F (0.3) B- (3.0) B (3.3) C+ (2.6) C (2.4)
2026-11-07 B- (2.9) F (0.2) C+ (2.5) B (3.4) A+ (5.0) C+ (2.8)
2026-10-31 D- (1.0) F (0.2) C+ (2.7) B+ (3.7) A+ (5.0) C+ (2.5)
2026-10-24 D- (1.0) F (0.3) C+ (2.7) B (3.4) A+ (5.0) C (2.5)
2026-10-17 D- (1.1) F (0.2) C+ (2.7) B (3.3) A+ (5.0) C (2.5)
Page 1 of 7